What Nanomi does

Nanomi B.V. is a Dutch pharmaceutical technology company headquartered in Oldenzaal, Netherlands, operating as a wholly owned subsidiary of Indian pharmaceutical group Lupin Limited since 2014. The company develops and manufactures microsphere and nanoparticle-based long-acting release injectable medicines, built around its proprietary PrecisionSphere™ particle control technology platform (patent-protected until 2038). PrecisionSphere delivers uniform particle size, shape, and biological properties, enabling consistent drug release over treatment durations ranging from weeks to months and improved injectability via smaller-gauge needles. The company's first commercial product, Risperidone Long-Acting Injectable, received U.S. FDA approval in September 2025 with 180-day Competitive Generic Therapy exclusivity and was launched in three dosage strengths (25 mg, 37.5 mg, 50 mg) targeting a combined USD 187 million U.S. market opportunity.

Nanomi operates a B2B platform-plus-products business model with three revenue streams: technology licensing and co-development of the PrecisionSphere platform with pharmaceutical and biotech partners; contract manufacturing and R&D services for complex injectable programs including formulation development, scale-up, and technology transfer; and proprietary product development, exemplified by the Risperidone launch. Primary customers are mid-size and big pharma companies developing parenteral or long-acting injectable assets, with biotechnology companies as a secondary segment. Pricing is not publicly disclosed and is quote-based. In 2026, Nanomi completed two strategic acquisitions: VISUfarma B.V. (a European ophthalmology company with 60+ branded products and EUR 48 million in 2024 revenue) effective April 1, 2026, and a controlling stake in Multicare Pharmaceuticals Philippines for up to USD 39.6 million. These acquisitions expand Nanomi's geographic footprint across five European countries and into Southeast Asia, and add a complementary ophthalmology therapeutic vertical alongside its core long-acting injectable platform.

The company employs approximately 50 people and operates from state-of-the-art formulation, process, and analytical chemistry laboratories under EU GMP Annex 1 and GMP compliance. Recent recognitions include a 2025 CMO Award for Life Science Leadership in Drug Delivery from Lupin and Great Place To Work certification. The business is positioned as Lupin's center of excellence for complex injectable long-acting release medicines, with a strategic partnership program actively pursuing external licensing of the PrecisionSphere platform to third-party pharma companies.

Name

Nanomi

Legal name

Nanomi B.V.

Website

https://nanomi.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Nanomi B.V. is a Dutch pharmaceutical technology subsidiary of Lupin Limited that develops microsphere and nanoparticle long-acting injectables using its proprietary PrecisionSphere platform, serving mid-size and big pharma partners via licensing, co-development, and contract manufacturing.

Ownership category

akta.pro rank

Product category

Long-Acting Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Long-acting injectables
• Pharmaceutical manufacturing
• Microsphere technology
• Drug delivery platforms
• Particle engineering

Headquarters

HQ city

Oldenzaal

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Technology Licensing and Co-development: Nanomi generates revenue through licensing its PrecisionSphere technology to pharmaceutical partners for development of long-acting injectable products. Offers flexible partnership models from co-development to full licensing.
2. Contract Manufacturing Services: Provides custom pharmaceutical manufacturing services and R&D services to pharma and biotech partners seeking expert input for feasibility decisions, complex injectable programs, and scale-up to commercial production.
3. Product Development: Develops proprietary pipeline of long-acting injectable products, with first product Risperidone receiving USFDA approval. Combined estimated US sales for dosage strengths stand at USD 187 million.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Nanomi develops and manufactures microsphere and nanoparticle-based long-acting release injectable medicines using its proprietary PrecisionSphere™ particle control technology, which delivers uniform particle size, shape, and biological properties enabling consistent controlled drug release over weeks to months. The company operates as a B2B pharmaceutical technology partner, offering technology licensing, co-development, and contract manufacturing services to pharma and biotech firms, alongside its own proprietary product pipeline led by Risperidone Long-Acting Injectable commercialized through parent Lupin.

Product overview

Nanomi operates as a pharmaceutical technology company with a platform-plus-products model. Its core offering is the PrecisionSphere™ proprietary technology platform for developing long-acting release injectable medicines with uniform particle characteristics. The company's first commercial product utilizing this platform is Risperidone Long-Acting Injectable, launched in November 2025. Additionally, Nanomi (as a Lupin subsidiary) acquired VISUfarma, adding a portfolio of 60+ branded ophthalmology products across European markets. Nanomi develops microsphere and nanoparticle-based long-acting release injectables, positioning itself as a CDMO partner while building its own product pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• PrecisionSphere™ Technology Platform Proprietary particle control technology platform for developing long-acting release injectable medicines with uniform particle size, shape, and biological properties. Enables consistent drug release over treatment durations ranging from weeks to months and improved injectability with smaller needles. Sold through technology licensing and co-development partnerships to pharmaceutical and biotechnology companies.
• Risperidone Long-Acting Injectable Extended-release injectable suspension for treating schizophrenia and bipolar I disorder in adults, available in three dosage strengths (25 mg, 37.5 mg, 50 mg single-dose vials). First commercial product utilizing the PrecisionSphere™ platform, bioequivalent to Risperdal Consta®. Combined estimated U.S. sales for the three dosage strengths stand at USD 187 million (IQVIA MAT September 2025). Commercialized by Lupin following FDA approval.
• Contract Manufacturing and R&D Services Custom pharmaceutical manufacturing and R&D services for pharma and biotech companies seeking expert input for feasibility decisions, complex injectable programs, and scale-up to commercial production. Includes technology transfer, scale-up support, and subject matter expertise for aseptic processing and sterile manufacturing.

Quantifiable outcome

• FDA approval achieved for Risperidone long-acting injectable with 180-day CGT exclusivity, demonstrating platform validation
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Multicare Pharmaceuticals Philippines (MPPI)coreStrategic or Co-development Partner · 2 April 2026Nanomi B.V., a wholly owned subsidiary of Lupin, acquired 43.38% stake in Multicare Pharmaceuticals Philippines from existing shareholders for up to $39.6 million. Acquisition expected to close by end of May 2026. Nanomi's stake was previously increased from 51% to 56.28% after MPPI buyback of shares.
• VISUfarma B.V.coreStrategic or Co-development Partner · 29 September 2025Lupin, through its wholly owned subsidiary Nanomi B.V., acquired VISUfarma B.V. from GHO Capital Partners. VISUfarma is a European ophthalmology pharmaceutical company with over 60 branded products and operations across Italy, UK, Spain, Germany, and France. VISUfarma generated €48 million in revenue in 2024. Transaction closed effective April 1, 2026.
• Contract Manufacturing Organizations (CMOs)coreOthersNanomi collaborates with CMOs and GMP-manufacturing sites for technology transfer, scale-up, and resolving technical challenges. Serves as subject matter expert for aseptic processing and sterile manufacturing.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Regional players

• Aenova Group: Aenova is a European-headquartered CDMO with strengths in sterile liquid and lyophilized parenterals and aseptic fill-finish capacity, serving the same EU and global specialty pharma clients that Nanomi targets; it competes for LAI contract manufacturing and technology-transfer engagements in the EU market.

Broad incumbents

• West Pharmaceutical Services: West Pharmaceutical Services supplies elastomeric components, containment systems, and integrated delivery platforms for injectables and is increasingly positioned as a partner in long-acting injectable device and formulation ecosystems; its role as an enabling supplier to LAI programs overlaps Nanomi's stakeholder map, including shared customers developing LAI products.
• Lonza: Lonza is one of the world's largest pharmaceutical CDMOs with full mammalian and parenteral capabilities, including increasingly aggressive expansion into complex injectables and LAI formulations through recent capacity investments; its scale and aseptic manufacturing depth make it the dominant broad incumbent competitor to specialty CDMOs like Nanomi.
• Catalent: Catalent (now part of Novo Holdings) operates one of the largest injectable drug product CDMO networks globally, including softgel and parenteral capabilities with significant overlap in LAI formulation and aseptic fill-finish; it is the most direct competitor to Nanomi's contract manufacturing and licensing services for parenteral long-acting injectables.

Direct peers

• Evonik Industries: Evonik's Health Care division markets RESOMER biodegradable polymers and provides CDMO services for long-acting injectables and parenteral drug products, with an EU-based particle engineering footprint that directly mirrors Nanomi's PrecisionSphere microsphere/nanoparticle platform; competes for the same partnership and licensing clients targeting complex injectables.
• Tolmar Pharmaceuticals: Tolmar is a specialty pharmaceutical company that develops and manufactures long-acting injectable polymer-based products (notably Eligard for prostate cancer using in-situ gel technology); it competes head-to-head with Nanomi in the LAI oncology and endocrine space and shares the model of proprietary long-acting injectable products plus licensing/CMO services.
• Bora Pharmaceuticals: Bora Pharmaceuticals operates injectables-focused CDMO and specialty manufacturing services including sterile injectables, ophthalmics, and complex dosage forms through acquisitions in Europe and the U.S.; its injectable CDMO footprint and recent expansion overlap Nanomi's region and customer profile, making it a relevant comparably scaled CDMO peer.
• Ascendia Pharmaceuticals: Ascendia is a specialty CDMO focused on complex parenteral formulations including nanoemulsions, liposomes, and microsphere-based injectables for poorly soluble or long-acting compounds; its formulation and analytical depth aligns precisely with Nanomi's PrecisionSphere-enabled services and customer base (small and mid-size pharma developing specialty injectables).
• Alkermes: Alkermes is the dominant independent player in long-acting injectable microsphere technology for CNS, with marketed products like Aristada (aripiprazole LAI) and Vivitrol (naltrexone LAI) and a native polymer-microsphere platform directly analogous to PrecisionSphere, making it the closest competitor and the benchmark Nanomi must beat in the LAI CNS market.

Emerging players

• Dalton Pharma Services: Dalton Pharma Services is a Toronto-based specialty CDMO providing formulation, sterile fill-finish, and analytical services for complex injectables and small-molecule drug products; its scale and service mix (microbiology, GMP manufacturing, analytical) directly parallel Nanomi's three-lab CDMO offering, making it a relevant emerging peer for LAI feasibility and scale-up work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nanomi

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanomi